HWG Holdings LP lifted its stake in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 385.8% during the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 51,760 shares of the medical equipment provider's stock after purchasing an additional 41,105 shares during the quarter. Boston Scientific accounts for about 2.3% of HWG Holdings LP's holdings, making the stock its 16th largest position. HWG Holdings LP's holdings in Boston Scientific were worth $5,222,000 as of its most recent filing with the SEC.
A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Parnassus Investments LLC increased its stake in Boston Scientific by 0.7% in the 4th quarter. Parnassus Investments LLC now owns 14,861 shares of the medical equipment provider's stock worth $1,327,000 after acquiring an additional 97 shares during the last quarter. Baldwin Investment Management LLC increased its stake in Boston Scientific by 1.2% in the 4th quarter. Baldwin Investment Management LLC now owns 8,740 shares of the medical equipment provider's stock worth $781,000 after acquiring an additional 102 shares during the last quarter. Evergreen Capital Management LLC increased its stake in Boston Scientific by 1.7% in the 4th quarter. Evergreen Capital Management LLC now owns 6,331 shares of the medical equipment provider's stock worth $565,000 after acquiring an additional 106 shares during the last quarter. PDS Planning Inc increased its stake in Boston Scientific by 1.5% in the 4th quarter. PDS Planning Inc now owns 7,474 shares of the medical equipment provider's stock worth $668,000 after acquiring an additional 113 shares during the last quarter. Finally, Paladin Wealth LLC increased its stake in Boston Scientific by 1.6% in the 1st quarter. Paladin Wealth LLC now owns 7,156 shares of the medical equipment provider's stock worth $722,000 after acquiring an additional 113 shares during the last quarter. 89.07% of the stock is currently owned by institutional investors.
Insiders Place Their Bets
In other Boston Scientific news, CEO Michael F. Mahoney sold 164,443 shares of the business's stock in a transaction that occurred on Thursday, May 1st. The stock was sold at an average price of $102.48, for a total transaction of $16,852,118.64. Following the sale, the chief executive officer now directly owns 1,535,706 shares of the company's stock, valued at $157,379,150.88. The trade was a 9.67% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP John Bradley Sorenson sold 4,572 shares of the company's stock in a transaction that occurred on Monday, May 5th. The shares were sold at an average price of $104.54, for a total value of $477,956.88. Following the transaction, the executive vice president now directly owns 18,705 shares in the company, valued at approximately $1,955,420.70. This represents a 19.64% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 411,970 shares of company stock valued at $42,406,693 over the last ninety days. 0.50% of the stock is owned by insiders.
Analyst Ratings Changes
Several equities analysts have recently commented on the company. Evercore ISI increased their price objective on Boston Scientific from $110.00 to $112.00 and gave the company an "outperform" rating in a research report on Thursday, April 24th. Erste Group Bank upgraded Boston Scientific to a "strong-buy" rating in a research report on Thursday, May 8th. Leerink Partners assumed coverage on Boston Scientific in a research report on Monday, June 16th. They set an "outperform" rating and a $118.00 price objective on the stock. Barclays increased their price objective on Boston Scientific from $118.00 to $125.00 and gave the company an "overweight" rating in a research report on Friday, April 25th. Finally, Robert W. Baird increased their price objective on Boston Scientific from $115.00 to $120.00 and gave the company an "outperform" rating in a research report on Thursday, April 24th. Twenty-two equities research analysts have rated the stock with a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat, Boston Scientific currently has a consensus rating of "Buy" and a consensus target price of $116.09.
Check Out Our Latest Report on Boston Scientific
Boston Scientific Price Performance
NYSE BSX opened at $101.35 on Monday. The company has a market capitalization of $149.95 billion, a PE ratio of 73.98, a price-to-earnings-growth ratio of 2.62 and a beta of 0.68. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.88 and a current ratio of 1.45. The business's fifty day moving average is $101.77 and its 200 day moving average is $99.17. Boston Scientific Corporation has a fifty-two week low of $71.88 and a fifty-two week high of $107.17.
Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings data on Wednesday, April 23rd. The medical equipment provider reported $0.75 EPS for the quarter, beating the consensus estimate of $0.67 by $0.08. Boston Scientific had a return on equity of 18.67% and a net margin of 11.58%. The business had revenue of $4.66 billion for the quarter, compared to the consensus estimate of $4.57 billion. During the same period in the previous year, the business earned $0.56 earnings per share. The business's revenue was up 20.9% on a year-over-year basis. Sell-side analysts predict that Boston Scientific Corporation will post 2.85 earnings per share for the current year.
Boston Scientific Profile
(
Free Report)
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Boston Scientific, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Boston Scientific wasn't on the list.
While Boston Scientific currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
